Literature DB >> 27911337

Effect of the Butyrate Prodrug Pivaloyloxymethyl Butyrate (AN9) on a Mouse Model for Spinal Muscular Atrophy.

Jonathan D Edwards1, Matthew E R Butchbach1,2,3,4,5.   

Abstract

Spinal muscular atrophy (SMA) is an early-onset motor neuron disease that leads to loss of muscle function. Butyrate (BA)-based compounds markedly improve the survival and motor phenotype of SMA mice. In this study, we examine the protective effects of the BA prodrug pivaloyloxymethyl butyrate (AN9) on the survival of SMNΔ7 SMA mice. Oral administration of AN9 beginning at PND04 almost doubled the average lifespan of SMNΔ7 SMA mice. AN9 treatment also increased the growth rate of SMNΔ7 SMA mice when compared to vehicle-treated SMNΔ7 SMA mice. In conclusion, BA prodrugs like AN9 have ameliorative effects on SMNΔ7 SMA mice.

Entities:  

Keywords:  AN9; Motor neuron disease; neonatal mouse; preclinical drug trial; spinal muscular atrophy

Mesh:

Substances:

Year:  2016        PMID: 27911337      PMCID: PMC5184770          DOI: 10.3233/JND-160187

Source DB:  PubMed          Journal:  J Neuromuscul Dis


  26 in total

1.  Effect of the cytostatic butyric acid pro-drug, pivaloyloxymethyl butyrate, on the tumorigenicity of cancer cells.

Authors:  A Aviram; A Rephaeli; M Shaklai; A Nudelman; I Ben-Dror; L Maron; E Rabizadeh
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 2.  The neurobiology of childhood spinal muscular atrophy.

Authors:  T O Crawford; C A Pardo
Journal:  Neurobiol Dis       Date:  1996-04       Impact factor: 5.996

3.  Sodium butyrate inhibits histone deacetylation in cultured cells.

Authors:  E P Candido; R Reeves; J R Davie
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

4.  Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy.

Authors:  Matthew E R Butchbach; Casey J Lumpkin; Ashlee W Harris; Luciano Saieva; Jonathan D Edwards; Eileen Workman; Louise R Simard; Livio Pellizzoni; Arthur H M Burghes
Journal:  Exp Neurol       Date:  2016-02-15       Impact factor: 5.330

5.  Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats.

Authors:  M J Egorin; Z M Yuan; D L Sentz; K Plaisance; J L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

6.  SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN.

Authors:  Thanh T Le; Lan T Pham; Matthew E R Butchbach; Honglai L Zhang; Umrao R Monani; Daniel D Coovert; Tatiana O Gavrilina; Lei Xing; Gary J Bassell; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2005-02-09       Impact factor: 6.150

7.  Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy.

Authors:  J Pearn
Journal:  J Med Genet       Date:  1978-12       Impact factor: 6.318

8.  Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy.

Authors:  Matthew E R Butchbach; Jonathan D Edwards; Arthur H M Burghes
Journal:  Neurobiol Dis       Date:  2007-05-05       Impact factor: 5.996

9.  Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences.

Authors:  G Vidali; L C Boffa; E M Bradbury; V G Allfrey
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

10.  Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy.

Authors:  Catia Andreassi; Carla Angelozzi; Francesco D Tiziano; Tiziana Vitali; Eleonora De Vincenzi; Alma Boninsegna; Marcello Villanova; Enrico Bertini; Antonella Pini; Giovanni Neri; Christina Brahe
Journal:  Eur J Hum Genet       Date:  2004-01       Impact factor: 4.246

View more
  3 in total

1.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

2.  Dietary tributyrin, an HDAC inhibitor, promotes muscle growth through enhanced terminal differentiation of satellite cells.

Authors:  Robert L Murray; Wei Zhang; Marie Iwaniuk; Ester Grilli; Chad H Stahl
Journal:  Physiol Rep       Date:  2018-05

3.  Drug treatment for spinal muscular atrophy type I.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2019-12-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.